Study of Urinary Removal of Gadolinium Contrast Agents After MRI Scans to Assess Excretion Patterns

What this Trial Is About

Researchers are studying how gadolinium contrast agents Gd-CAs, used in MRI scans, are removed from the body through urine. Gadolinium is a rare earth element that is toxic in its isolated form but is safely used in complex molecules during MRI imaging. This study aims to describe the urinary excretion patterns of these agents to explore ways of recovering gadolinium and prevent environmental contamination. Participants with a prescription for MRI involving gadolinium contrast agents will have urine samples collected before the injection and multiple times up to two and a half hours after the injection. Blood samples are also collected before the injection. The focus is on measuring how much gadolinium is excreted in the urine shortly after MRI scans. During the study, participants will provide urine and blood samples around their MRI appointment. Researchers will assess kidney function, urine volume, and the timing of the first spontaneous urination after injection. They will also monitor study refusal rates and premature exits. The study continues until April 2028, with primary measurements taken within two and a half hours post-injection.

Kinetics of Urinary Excretion of Gadolinium Contrast Agents Used in MRI Examinations